ProQR Therapeutics (PRQR) Operating Leases (2017 - 2025)

ProQR Therapeutics' Operating Leases history runs 9 years deep, the most recent figure standing at $11.1 million for Q4 2025.

• In Q4 2025, Operating Leases fell 6.03% year-over-year to $11.1 million; the TTM figure through Dec 2025 stood at $11.1 million (down 6.03% YoY), while the FY2025 annual figure was $11.1 million, down 6.03% from the prior year.
• Operating Leases came in at $11.1 million for Q4 2025 at ProQR Therapeutics, down from $11.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $18.6 million in Q2 2021 to a low of $18611.0 in Q1 2021.
• A 5-year average of $14.0 million and a median of $14.9 million in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases slumped 94.49% in 2021 and surged 86630.68% in 2022, its largest moves.
• ProQR Therapeutics' Operating Leases stood at $16.9 million in 2021, then declined by 16.47% to $14.1 million in 2022, then rose by 5.57% to $14.9 million in 2023, then fell by 20.51% to $11.8 million in 2024, then decreased by 6.03% to $11.1 million in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $11.1 million, $11.8 million, and $14.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison